Alexza Pharmaceuticals, Inc. (ALXA) Posts Q2 EPS Loss of $0.13
Get Alerts ALXA Hot Sheet
Join SI Premium – FREE
Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) reported Q2 EPS of ($0.13), $0.02 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $1.26 million versus the consensus estimate of $430 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Evogene (EVGN) Tops Q2 EPS by 15c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share